Literature DB >> 25441731

Increased risk of post-operative complications in patients with Crohn's disease treated with anti-tumour necrosis factor α agents - a systematic review.

Alaa El-Hussuna1, Klaus Theede, Gunnar Olaison.   

Abstract

INTRODUCTION: Tumour necrosis factor α (TNF-α) plays a role in the immune defence, angiogenesis and collagen synthesis. Inhibition of these pathways may increase the risk of infections and impair wound healing in patients after surgery. Biologic treatments including anti-TNF-α agents are increasingly used in the treatment of inflammatory bowel disease. Taking into consideration the biologics' mechanism of action, fears have been expressed that they might increase the rate of post-operative complications. Results from 18 retrospective studies were conflicting, and meta-analyses based on these studies did not agree. The objective of this study was to review data from present reviews and meta-analyses in an attempt to come to conclusions for the use of anti-TNF-α in Crohn's disease patients in clinical practice.
METHODS: Literature search using both electronic and manual searches was conducted according to a pre-defined protocol. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were applied.
RESULTS: Two systematic reviews and six meta-analyses were found. Meta-analyses that included a large number of patients and applied quality assessment showed an increased risk of overall post-operative complications and an increased rate of infectious or anastomosis-related complications in patients receiving anti-TNF-α.
CONCLUSION: The use of anti-TNF-α agents in Crohn's disease patients is associated with an increased risk of post-operative complications after abdominal surgery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25441731

Source DB:  PubMed          Journal:  Dan Med J        ISSN: 2245-1919            Impact factor:   1.240


  9 in total

1.  Risk of postoperative morbidity in patients having bowel resection for colonic Crohn's disease.

Authors:  Igors Iesalnieks; A Spinelli; M Frasson; F Di Candido; B Scheef; N Horesh; M Iborra; H J Schlitt; A El-Hussuna
Journal:  Tech Coloproctol       Date:  2018-12-12       Impact factor: 3.781

2.  Early surgery in Crohn's disease a benefit in selected cases.

Authors:  Vinna An; Lauren Cohen; Matthew Lawrence; Michelle Thomas; Jane Andrews; James Moore
Journal:  World J Gastrointest Surg       Date:  2016-07-27

Review 3.  Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis.

Authors:  Christopher Alexakis; Richard Cg Pollok
Journal:  World J Gastrointest Surg       Date:  2015-12-27

Review 4.  Preoperative optimization of patients with inflammatory bowel disease undergoing gastrointestinal surgery: a systematic review.

Authors:  Marie Strøm Zangenberg; Nir Horesh; Uri Kopylov; Alaa El-Hussuna
Journal:  Int J Colorectal Dis       Date:  2017-10-19       Impact factor: 2.571

5.  Association of Preoperative Anti-Tumor Necrosis Factor Therapy With Adverse Postoperative Outcomes in Patients Undergoing Abdominal Surgery for Ulcerative Colitis.

Authors:  Audrey S Kulaylat; Afif N Kulaylat; Eric W Schaefer; Andrew Tinsley; Emmanuelle Williams; Walter Koltun; Christopher S Hollenbeak; Evangelos Messaris
Journal:  JAMA Surg       Date:  2017-08-16       Impact factor: 14.766

Review 6.  Biologics and surgical outcomes in Crohn's disease: is there a direct relationship?

Authors:  Abel Botelho Quaresma; Takayuki Yamamoto; Paulo Gustavo Kotze
Journal:  Therap Adv Gastroenterol       Date:  2020-07-16       Impact factor: 4.409

7.  No effect of anti-TNF-α agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study.

Authors:  Alaa El-Hussuna; Niels Qvist; Marie Strøm Zangenberg; Anne Langkilde; Volkert Siersma; Sara Hjort; Ismail Gögenur
Journal:  BMC Surg       Date:  2018-11-03       Impact factor: 2.102

8.  Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience.

Authors:  Bo Shen; Aimee Blake; Karen Lasch; Michael Smyth; Fatima Bhayat
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-08-21

9.  Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn's Disease Recurrence.

Authors:  Jongwook Yu; Hye Kyung Hyun; Jihye Park; Eun Ae Kang; Soo Jung Park; Jae Jun Park; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Gut Liver       Date:  2022-05-13       Impact factor: 4.519

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.